Skip to main content

Advertisement

Fig. 2 | Cancer Communications

Fig. 2

From: Carbon ion radiotherapy boost in the treatment of glioblastoma: a randomized phase I/III clinical trial

Fig. 2

The flow chart of the current Phase I/III trial. In the Phase I, the maximal tolerable dose (MTD) of the induction CIRT boost will be determined. The MTD will then be used in the experimental t arm in the Phase III of this trial. The Phase III aims to determine the overall survival, progression-free survival, and tumor response. GBM glioblastoma, AA anaplastic astrocytoma, DLT dose-limiting toxicity, CIRT carbon ion radiotherapy, PRT proton radiotherapy, TMZ temozolomide

Back to article page